Zimberelimab
Zimberelimab is a pharmaceutical drug with 52 clinical trials. Currently 33 active trials ongoing. Historical success rate of 72.7%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
23
Early Stage
25
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
61.5%
8 of 13 finished
38.5%
5 ended early
33
trials recruiting
52
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Clinical Trials (52)
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Study of GS-4528 in Adults With Solid Tumors
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Domvanalimab and Zimberelimab in Advanced Liver Cancers
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Switch Maintenance in Pancreatic
AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
AB154 Combined With AB122 for Recurrent Glioblastoma
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 52